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Conventional measurement of blood pressure (BP) at the doctor’s office is considered as the standard method for 
hypertension diagnosis and management.1 However, white- 
coat and masked hypertension phenomena are common in both 
untreated and treated patients. Assessment of out-of-office BP 
with ambulatory or home monitoring is therefore necessary for 
an accurate diagnosis and management.1
According to the European Society of Hypertension rec-
ommendations, white-coat and masked hypertension can be 
diagnosed using ambulatory or home BP measurements, with 
See Editorial Commentary, pp 670–671
Abstract—Home blood pressure monitoring is useful in detecting white-coat and masked hypertension and is recommended 
for patients with suspected or treated hypertension. The prognostic significance of white-coat and masked hypertension 
detected by home measurement was investigated in 6458 participants from 5 populations enrolled in the International 
Database of HOme blood pressure in relation to Cardiovascular Outcomes. During a median follow-up of 8.3 years, 
714 fatal plus nonfatal cardiovascular events occurred. Among untreated subjects (n=5007), cardiovascular risk was 
higher in those with white-coat hypertension (adjusted hazard ratio 1.42; 95% CI [1.06–1.91]; P=0.02), masked 
hypertension (1.55; 95% CI [1.12–2.14]; P<0.01) and sustained hypertension (2.13; 95% CI [1.66–2.73]; P<0.0001) 
compared with normotensive subjects. Among treated patients (n=1451), the cardiovascular risk did not differ between 
those with high office and low home blood pressure (white-coat) and treated controlled subjects (low office and 
home blood pressure; 1.16; 95% CI [0.79–1.72]; P=0.45). However, treated subjects with masked hypertension (low 
office and high home blood pressure; 1.76; 95% CI [1.23–2.53]; P=0.002) and uncontrolled hypertension (high 
office and home blood pressure; 1.40; 95% CI [1.02–1.94]; P=0.04) had higher cardiovascular risk than treated 
controlled patients. In conclusion, white-coat hypertension assessed by home measurements is a cardiovascular risk 
factor in untreated but not in treated subjects probably because the latter receive effective treatment on the basis 
of their elevated office blood pressure. In contrast, masked uncontrolled hypertension is associated with increased 
cardiovascular risk in both untreated and treated patients, who are probably undertreated because of their low office 
blood pressure.  (Hypertension. 2014;63:675-682.) • Online Data Supplement
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white-coat hypertension defined as elevated office and low 
ambulatory or home BP, and masked hypertension the reverse.1 
However, the European recommendations state that ambulatory 
and home BP monitoring might not be fully interchangeable 
methods.1 The role of ambulatory BP monitoring in predicting 
cardiovascular events has been well established,1 whereas for 
home BP monitoring until recently there was only 1 outcome 
study.2 In the past years, more prognostic data for home BP 
became available.3–5 Home BP monitoring is being widely used 
in several countries, and current guidelines in Europe and the 
US recommend its use in all treated patients with hypertension 
and in untreated subjects with suspected hypertension.6,7
The International Database of HOme blood pressure in 
relation to Cardiovascular Outcome (IDHOCO) has been con-
structed using individual participants’ data of published pop-
ulation studies that evaluated the prognostic value of home 
BP.8,9 The collective analysis of the available outcome stud-
ies provided adequate power to allow the investigation of the 
prognostic significance of white-coat and masked hyperten-
sion phenomena separately in untreated and treated subjects, 
which was the objective of this article.
Methods
Study Population
The IDHOCO database8 has been constructed using individual sub-
jects’ data including information on subsequent fatal and nonfatal 
outcomes obtained from 5 population studies of home BP monitor-
ing performed in Ohasama, Japan (n=2777),10,11 Finland (Finn-Home; 
n=2075),3 Tsurugaya, Japan (n=836),12 Didima, Greece (n=665),13 
and Montevideo (n=400).14 The classification and number of events, 
and baseline characteristics have been published.8,9 Of a total of 6753 
participants in the IDHOCO database, 295 participants were excluded 
(284 with <2 office or home BP readings; 10 with missing informa-
tion for baseline treatment; 1 without information on cardiovascular 
disease history).8
Office and Home BP Measurements
At least 2 baseline office and home BP measurements were required 
for inclusion. Office measurements were taken using electronic (3 
studies)10,12,14 or mercury manometers (2 studies),3,13 in a single visit 
(4 studies)3,10,12,14 or 2 visits (1 study),13 and the average number of BP 
readings per study ranged from 1.8 to 6.8 Home measurements were 
taken using validated electronic arm devices in the morning and eve-
ning (4 studies),3,10,13,14 or only the morning (1 study),12 and the total 
number of BP readings averaged per study ranged from 2 to 45.9 (4 
studies including 94% of the participants provided an average of ≥12 
readings).3,10,12,13 Home monitoring was performed only at baseline 
within 1 to 26 days (≥7 days in 84% of the participants).3,10,12 Office 
BP measurements of a single visit and all available home measure-
ments of each individual were averaged to give a single number for 
office and home BP, respectively.
Definitions of White-coat, Masked, and  
Sustained Hypertension
White-coat hypertension was defined as office systolic BP≥140 mm Hg 
and/or diastolic BP≥90 mm Hg, with home systolic BP<135 mm Hg 
and diastolic BP<85 mm Hg. Masked hypertension was defined as 
home systolic BP≥135 mm Hg and/or diastolic BP≥85 mm Hg, with 
office systolic BP<140 mm Hg and diastolic BP<90 mm Hg. Sustained 
hypertension was defined as elevated office BP (systolic≥140 mm Hg 
and/or diastolic≥90 mm Hg) and home (systolic BP≥135 mm Hg 
and/or diastolic BP≥85 mm Hg) and normotension as low office (sys-
tolic BP<140 mm Hg and diastolic BP<90 mm Hg) and home (systolic 
BP<135 mm Hg and diastolic BP<85 mm Hg).
End Points
The primary analysis was based on a composite cardiovascular end 
point, which included fatal cardiovascular events, nonfatal myocar-
dial infarction, surgical and percutaneous coronary revasculariza-
tion, heart failure, pacemaker implantation, and stroke. Only the first 
cardiovascular event for each participant during the study  follow-up 
was accepted for analysis. A secondary analysis including only fatal 
events (cardiovascular and other) was also performed.
Analysis
The statistical software SAS version 9.3 (SAS Institute, Cary, NC) 
was used. Means and proportions were compared using the standard 
normal z test for large samples or ANOVA and the χ2 statistic, respec-
tively. Kruskal–Wallis test was used to assess differences among 
subjects with normotension, white-coat, masked, and sustained 
hypertension. Kaplan–Meier survival curves for cardiovascular 
events and total mortality were provided in the 4 subgroups, untreated 
and treated, with ad hoc comparisons (P values with Sidak correc-
tion) of normotensives versus subjects with white-coat, masked, and 
sustained hypertension.
In multivariable-adjusted Cox regression, the hazard ratio for car-
diovascular events in subjects with white-coat, masked, and sustained 
hypertension compared with normotensive subjects was evaluated. 
Untreated and treated subjects were analyzed separately. Covariables 
were cohort, sex, age, body mass index, serum cholesterol, smoking, 
history of cardiovascular disease, and diabetes mellitus. Sensitivity anal-
ysis was performed by excluding 1 cohort at a time to confirm that the 
results are consistent across all studies and not driven by a single cohort.
Results
A total of 6458 subjects were included, with 59 239 person- 
years of follow-up (median 8.3 years; 5th to 95th percentile 
interval, 4.2–16.8 years). At baseline, 5007 subjects were not 
on antihypertensive drug treatment (77.5%), whereas 1451 
(22.5%) subjects were treated. A total of 714 cardiovascular 
events occurred during the follow-up (412 in untreated and 302 
in treated subjects) and 809 deaths (520 and 289, respectively).
The baseline characteristics of the study participants accord-
ing to treatment status and the classification into normotensive 
and white-coat, masked, and sustained hypertension are pre-
sented in Table 1. Subjects with masked hypertension were 
older, had higher incidence of smoking and diabetes mellitus, 
and tended to have cardiovascular disease history more often 
than normotensives or subjects with white-coat hypertension 
(untreated and treated). In white-coat and masked hypertension 
subjects, both untreated and treated, body mass index, total cho-
lesterol, and office and home BP were higher than in normo-
tensives but lower than in subjects with sustained hypertension. 
Treated subjects (n=1451) were older (66.6 versus 57.1 years), 
more likely to have diabetes mellitus (15.6% versus 6.4%) 
and cardiovascular disease history (23.1% versus 6.5%), less 
likely to smoke (14.2% versus 22.9%), and had higher body 
mass index (26.2 versus 25.1 kg/m2) and BP (office 144.4/82.7 
versus 130.9/77.9 mm Hg; home 138.6/80.3 versus 123.9/74.9 
mm Hg) than untreated subjects (n=5007; all P<0.0001).
Among subjects with low office BP (normotension and 
masked hypertension), the proportion of those with elevated 
home BP (masked hypertension) was higher in treated than in 
untreated subjects (41.4% versus 11.9%; P<0.0001). On the 
contrary, among subjects with elevated office BP (sustained 
plus white-coat hypertension), the proportion of those with low 
home BP (white-coat hypertension) was higher in untreated 
than in treated subjects (42.9% versus 25.8%; P<0.0001).
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Hazard ratios for cardiovascular events in untreated and 
treated subjects with white-coat, masked, and sustained 
hypertension are presented in Table 2 and Kaplan–Meier sur-
vival curves in the Figure. Treated normotensive subjects had 
54% higher cardiovascular risk than untreated normotensives.
In the untreated group, normotensive subjects had lower 
cardiovascular risk than subjects with white-coat, masked, 
and sustained hypertension. The hazard ratio was progres-
sively increased, from normotensives to subjects with white- 
coat (1.42), masked (1.55), and sustained hypertension 
(2.13), but with considerable overlap in their 95% confidence 
intervals (CI; P<0.0001 for trend). In the treated group, 
the hazard ratio of subjects with white-coat hypertension 
did not differ from treated normotensive patients. As in the 
untreated group, treated subjects with masked or sustained 
hypertension had higher risk than treated subjects with low 
office and home BP (P≤0.039).
The hazard ratios for total mortality in untreated and 
treated subjects with white-coat, masked, and sustained 
hypertension are presented in Table 3 and Kaplan–Meier 
survival curves in the Figure. All-cause mortality rates were 
similar in treated and untreated subjects with normal office 
and home BP (hazard ratio, 1.10). Subjects with white-coat 
hypertension, untreated and treated, did not have higher mor-
tality risk than the respective normotensive group (hazard 
ratio, 1.13 and 1.19, respectively; P=0.37). On the contrary, 
subjects with masked hypertension had higher risk than nor-
motensive subjects, both untreated and treated (P≤0.031). 
Untreated subjects with sustained hypertension had higher 
risk than normotensive subjects (P=0.012).
Table 1. Baseline Characteristics in Untreated and Treated Subjects With Normotension and White-Coat, Masked, and Sustained 
Hypertension
Untreated Participants Treated Participants
Characteristics Normotension White-Coat HT Masked HT Sustained HT Normotension White-Coat HT Masked HT Sustained HT
Subjects, n 2984 695 404 924 328 230 232 661
Age, y 53.7±13.6 58.8±12.1* 62.7±11.6* 64.3±11.5* 65.5±10.4 64.3±10.6 67.7±9.6† 67.6±9.7†
Sex, women 1830 (61.3) 371 (53.4)† 179 (44.3)* 458 (49.6)* 214 (65.2) 137 (59.6) 112 (48.3)* 374 (56.6)†
Ethnicity, white 1482 (49.7) 324 (46.6) 184 (45.5) 531 (57.5)* 107 (32.6) 102 (44.4)† 79 (34.1) 318 (48.1)*
BMI, kg/m2 24.3±3.6 25.1±3.8* 26.2±4.6* 26.8±4.6* 24.9±3.9 25.8±4.3‡ 26.1±5.2† 27.0±4.8*
Current smoking 692 (23.2) 140 (20.1) 120 (29.7)† 193 (20.9) 35 (10.7) 25 (10.9) 50 (21.6)§ 94 (14.4)
Total cholesterol, mmol/L 5.3±1.0 5.5±1.1* 5.4±1.1‡ 5.8±1.2* 5.3±1.1 5.5±0.9‡ 5.3±1.0 5.7±1.1*
Diabetes mellitus 152 (5.1) 43 (6.2) 47 (11.6)* 76 (8.2)§ 39 (11.9) 31 (13.5) 48 (20.7)† 108 (16.3)
Cardiovascular disease 155 (5.2) 48 (6.9) 37 (9.2)† 87 (9.4)* 82 (25.0) 52 (22.6) 64 (27.6) 137 (20.7)
Systolic office BP 119.4±11.7 147.8±11.2* 128.3±8.1* 156.2±16.0* 125.2±9.5 149.8±12.9* 128.6±8.7† 157.5±16.0*
Systolic home BP 114.2±10.1 123.6±8.0* 140.3±9.3* 148.3±13.1* 121.8±8.5 124.5±7.4† 143.5±10.6* 150.2±13.8*
Diastolic office BP 72.6±8.5 86.0±9.4* 76.7±8.3* 89.9±10.3* 73.9±8.1 85.3±11.1* 75.7±8.8‡ 88.6±10.6*
Diastolic home BP 70.2±7.1 75.1±6.3* 84.0±7.4* 85.9±8.7* 72.7±6.8 75.1±6.3§ 83.3±7.7* 84.8±9.3*
Mean±SD, % in parentheses. BMI indicates body mass index; BP, blood pressure, mm Hg; and HT, hypertension.
*P<0.0001.
†P<0.01.
‡P<0.05.
§P<0.001 for difference versus normotensives; ANOVA or χ2 test for comparison among the 4 subgroups (untreated or treated separately) significant for all 
characteristics (P<0.05), apart from cardiovascular disease in treated subjects.
Table 2. Hazard Ratios for Cardiovascular Events in Untreated and Treated Subjects With White-Coat, Masked, 
and Sustained Hypertension
Untreated Participants Treated Participants
Subgroup
Subjects
N
Events
n
Adjusted HR  
(95% CI)
P  
Value
Subjects
N
Events
n
Adjusted HR  
(95% CI)
P 
Value
Normotensives 2984 154 1.00 328 57 1.54 (1.11–2.14) 0.01
328 57 1.00
White-coat HT 695 64 1.42 (1.06–1.91) 0.019 230 45 1.16 (0.79–1.72) 0.45
Masked HT 404 53 1.55 (1.12–2.14) 0.008 232 66 1.76 (1.23–2.53) 0.002
Sustained HT 924 141 2.13 (1.66–2.73) <0.0001 661 134 1.40 (1.02–1.93) 0.039
Total 5007 412 1451 302
In the untreated group, hazard ratios express the risk versus untreated normotensives. In the treated group, the hazard ratio of treated 
normotensives express the risk versus untreated normotensives, whereas the hazard ratios of treated white-coat, masked, and sustained 
hypertensives express the risk versus treated normotensives. Hazard ratios were adjusted for cohort, sex, age, body mass index, serum 
cholesterol, smoking status, cardiovascular disease history, and diabetes mellitus. CI indicates confidence intervals; HR, hazard ratio; and 
HT, hypertension.
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Sensitivity analyses in untreated subjects showed that 
the cardiovascular risk was 69% (95% CI [17%, 145%]; 
P=0.0055) higher in men with white-coat hypertension com-
pared with normotensive men, whereas the risk in women 
with white-coat hypertension was similar to that in normo-
tensive women (hazard ratio, 1.13; 95% CI [−32%, 87%]; 
P=0.63). Similarly, men with masked hypertension had 69% 
(95% CI [13%, 155%]; P=0.011) higher cardiovascular risk 
than normotensive men, whereas the risk in women with 
masked hypertension was similar to that in normotensive 
women (hazard ratio, 1.28; 95% CI [0.75, 2.20]; P=0.37). 
Hazard ratios were not significantly different between men 
and women. Further sensitivity analyses performed by 
excluding 1 cohort at a time revealed a consistent trend (haz-
ard ratios always to the same direction) toward increased 
cardiovascular risk in untreated subjects with white-coat, 
masked, and sustained hypertension compared with untreated 
normotensive subjects, and in treated, masked, and sustained 
hypertension compared with treated normalized hypertension 
(Table S1 in the online-only Data Supplement).
Discussion
The IDHOCO project is unique in that it provides a world-
wide, integrated, general population-based, participant level 
database with data on the prognostic value of home BP mea-
surements. In contrast to each of the individual outcome 
studies, the IDHOCO database provided the adequate power 
to allow the investigation of the prognostic significance of 
white-coat and masked hypertension separately in untreated 
and treated subjects. Moreover, this type of meta-analysis is 
superior to literature-based, summary statistics-based meta- 
analyses because it provides the ability to include the comput-
ing survival curves, to check whether the proportional hazard 
assumption is fulfilled, and test several interactions.15,16
This analysis of home measurements confirms previous 
reports using ambulatory BP monitoring that masked hyper-
tension is associated with increased cardiovascular risk in both 
untreated and treated subjects (Table S2).17,18 Thus, masked 
hypertension is a risk factor irrespective of the treatment status 
and the measurement method (home or ambulatory). However, 
the novel information provided by this analysis is that the 
Table 3. Hazard Ratios for Total Mortality in Untreated and Treated Subjects With White-Coat, Masked, and 
Sustained Hypertension
Untreated Participants Treated Participants
Subgroup
Subjects
N
Events
n
Adjusted HR  
(95% CI)
P 
Value
Subjects
N
Events
n
Adjusted HR  
(95% CI)
P 
Value
Normotensives 2984 239 1.00 328 62 1.10 (0.81–1.48) 0.55
328 62 1.00
White-coat HT 695 75 1.13 (0.87–1.46) 0.37 230 50 1.19 (0.82–1.73) 0.37
Masked HT 404 76 1.36 (1.04–1.77) 0.024 232 60 1.49 (1.04–2.14) 0.031
Sustained HT 924 130 1.34 (1.07–1.68) 0.012 661 117 1.19 (0.87–1.64) 0.28
Total 5007 520 1451 289
In the untreated group, hazard ratios express the risk versus the untreated normotensives. In the treated group, the hazard ratio of treated 
normotensives express the risk versus the untreated normotensives, whereas the hazard ratios of treated white-coat, masked, and sustained 
hypertensives express the risk versus the treated normotensives. Hazard ratios were adjusted for cohort, sex, age, body mass index, serum 
cholesterol, smoking status, cardiovascular disease history, and diabetes mellitus. CI indicates confidence intervals; HR, hazard ratio; and 
HT, hypertension.
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risk associated with white-coat hypertension is increased 
in untreated but not in treated subjects. The International 
Database on Ambulatory blood pressure monitoring in rela-
tion to Cardiovascular Outcomes (IDACO) database, which 
included ambulatory instead of home BP data, did not show a 
difference in the prognosis of white-coat or masked hyperten-
sion in treated versus untreated subjects (Table S2).17,18 Thus, 
these data suggest that in untreated subjects the prognostic rel-
evance of white-coat hypertension might differ according to 
the method used for out-of-office BP evaluation (home versus 
ambulatory monitoring), although it should be mentioned that 
the IDACO and IDHOCO databases differ in more aspects 
than only the out-of-office BP monitoring method.
Prevalence of White-Coat and Masked 
Hypertension
In the present study, white-coat hypertension was detected 
in 14.3% of the participants and, masked hypertension was 
detected in 9.8% of the participants, compared with 10.6% 
and 14.6%, respectively, in the IDACO database that also used 
single-visit office BP but daytime ambulatory instead of home 
BP.17 However, among subjects with elevated office BP, white- 
coat hypertension was common, particularly in the untreated 
group (42.9%). This is probably because this analysis is based 
on single-visit office BP, which is known to be reduced in sub-
sequent visits. Moreover, treated subjects are more familiar 
with the office environment, which might have reduced their 
office BP. On the contrary, among subjects with low office 
BP, masked hypertension was 3-fold more common in treated 
than in untreated subjects. This difference may be attributed to 
the fact that the antihypertensive treatment is mainly adjusted 
according to office BP, and that in treated subjects office BP 
is usually taken close to the peak effect of the drug treatment 
(few hours after morning drug intake), whereas home BP is 
measured at the trough (morning) and the plateau effect of 
treatment (evening). Moreover, treated subjects are more 
familiar with the office setting, which might have reduced their 
office BP. However, the prevalence of masked hypertension is 
particularly alarming (41.4% of treated subjects with normal-
ized office BP and 16% of all treated subjects) and highlights 
the need for out-of-office BP evaluation in all treated subjects.
In the IDACO database in 648 untreated subjects with iso-
lated systolic hypertension on office measurement, 52% had 
white-coat hypertension defined by ambulatory BP monitor-
ing.18 In the same database, the prevalence of masked hyper-
tension among untreated subjects with normal office BP was 
19.2% compared with 31.9% in treated subjects.19 In the 
absence of studies assessing home and ambulatory BP in the 
same subjects, it is difficult to conclude whether the prevalence 
of white-coat and masked hypertension differs when defined by 
ambulatory or home measurements. The Pressione Arteriose 
Monitorate E Loro Associazioni (PAMELA) outcome study 
that performed office, home, and 24-hour ambulatory BP mea-
surements in a general population sample of 2051 subjects 
in Italy20,21 showed similar prevalence of masked hyperten-
sion detected by home or ambulatory monitoring and slightly 
higher prevalence of white-coat hypertension with ambulatory 
monitoring. However, in the PAMELA study, the potential of 
home BP monitoring has not been exhausted because only 2 
home readings were obtained, which are known to give higher 
and more variable values than measurements during the next 
days22 and less predictive of stroke risk.23 Cross-sectional stud-
ies reported similar proportions of white-coat and masked 
hypertension detected by home or ambulatory monitoring with 
reasonable diagnostic agreement between the 2 methods.24,25
Cardiovascular Event Rate in Untreated Versus 
Treated Subjects
Treated subjects were at significantly higher cardiovascular 
risk than the untreated ones, after adjustment for several major 
risk factors, many of whom were more prevalent in the treated 
group. Interestingly, treated subjects with low office and home 
BP had 54% higher cardiovascular risk than untreated normo-
tensives. This has previously been noted in outcome studies 
with ambulatory BP monitoring17 and suggests that treatment, 
per se, is a marker for undetectable residual confounding risk 
factors, which are not eliminated by treatment.
This study showed that in untreated subjects, white-coat 
hypertension defined by home BP measurement is associated 
with higher cardiovascular risk than normotension. This is 
probably related, at least in part, to the higher home BP levels 
compared with the normotensive subjects. Sensitivity analy-
ses suggested that this finding was limited to men who are 
at higher cardiovascular risk than women. In fact, white-coat 
hypertension seemed to have similar risk to that of masked 
hypertension but lower than that of sustained hypertension 
(Table 2). During the long follow-up (median 8.3 years), sev-
eral individuals with prehypertension might have developed 
sustained hypertension. It is clear from the Figure that it takes 
a long time for the event curves to clearly separate, which is 
supported by similar data with ambulatory BP monitoring.26
On the contrary, in the treated group, the white-coat phe-
nomenon did not seem to be related with increased cardiovas-
cular risk, which might be because of effective treatment of 
these subjects on the basis of their elevated office BP27 and to 
the higher risk in the reference group. On the contrary, treated 
subjects with masked hypertension were at significantly higher 
risk than normotensive subjects and subjects with white-coat 
hypertension, which might be attributed to inadequate treat-
ment of these patients because of their low office BP.
The lack of the prognostic value of the office BP in treated 
patients is supported by previous reports. The Ohasama study 
suggested a weakness of office BP for prediction of stroke risk 
in treated patients in contrast to home BP.28 Some of the partici-
pants originally with white-coat hypertension are expected to 
move to normotension group by antihypertensive medication 
during follow-up, which might have attenuated the difference 
in the risk between normotension and white- coat hypertension. 
In addition, a meta-analysis showed that the treatment-induced 
BP reduction is smaller for ambulatory than for office BP.29 
These findings explain, at least in part, the fact that a propor-
tion of treated patients originally classified to the sustained 
hypertension group is assigned to masked hypertension when 
treatment is initiated. In a recent IDACO analysis, the preva-
lence of masked hypertension was higher in treated individuals 
compared with untreated ones (42.5% versus 29.3%, respec-
tively, for patients with diabetes mellitus and 30.4% versus 
18.8% for nondiabetic patients).19 These observations may 
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account for the high cardiovascular risk in masked hyperten-
sion comparable with that in sustained hypertension.
Previous reports from the IDACO database based on ambu-
latory BP monitoring also provided information on the prog-
nosis of white-coat and masked hypertension in untreated 
versus treated subjects.17,18 These 2 international databases 
have similar numbers of participants and follow-up (Table 
S2) and provide a unique opportunity to address the question 
whether white-coat and masked hypertension have similar 
prognostic value when identified by ambulatory or home BP 
measurements, although this would ideally require a data set 
including these measurements in the same subjects.
In contrast to the current analysis, in the IDACO database, 
untreated and treated white-coat hypertension assessed by 
ambulatory monitoring was not associated with increased 
cardiovascular risk compared with normotension, whereas 
masked hypertension did carry increased cardiovascular risk 
(Table S2).17 Another IDACO analysis in elderly subjects with 
isolated systolic hypertension also showed white-coat hyper-
tension not to be associated with increased cardiovascular risk 
in both untreated and treated subjects.18 However, there was a 
trend toward higher risk in untreated versus treated subjects 
with white-coat hypertension compared with normotension 
(Table S2). Moreover, in the latter analysis, the cardiovascu-
lar risk of white-coat hypertension versus normotension was 
higher in untreated men and subjects with diabetes mellitus.18 
The SHEAF (Self-measurement of blood pressure at Home 
in the Elderly: Assessment and Follow-up) study in treated 
elderly subjects assessed with home BP measurements is in 
line with the present findings by showing treated patients with 
white-coat hypertension to have similar cardiovascular risk 
as patients with controlled hypertension and subjects with 
masked hypertension to be at high risk similar to patients with 
sustained hypertension.30
The finding that untreated white-coat hypertension is asso-
ciated with increased risk when identified by home BP moni-
toring, whereas this was not the case in previous analysis with 
ambulatory BP monitoring, is challenging. The view that home 
and ambulatory BP are interchangeable methods because they 
both provide multiple out-of-office measurements is rather 
simplistic. These methods have major differences because 
home BP is monitored for several days, weeks, or months, 
but only in the sitting posture at home, whereas ambulatory 
BP is monitored only for 24 hours but in different conditions, 
at work, at home, and during sleep. The present study sug-
gests that home and ambulatory BP are not interchangeable 
but probably complementary methods. This view is supported 
by a recent analysis of the PAMELA general population study 
where among subjects with white-coat hypertension (elevated 
office and low home or ambulatory BP) those with low home 
and ambulatory BP had lower cardiovascular mortality than 
those with only one of them being low.31
Terminology for White-Coat and Masked 
Hypertension
The terms white-coat and masked hypertension were used in 
this article to present the disagreement between office and 
home BP measurements in both untreated and treated sub-
jects. It is accepted, however, that these terms are appropriate 
for untreated subjects only. In the recent European Society of 
Hypertension position article on ambulatory BP monitoring, 
the terms white-coat effect and masked uncontrolled hyper-
tension are used for treated individuals.32 Franklin et al distin-
guished unnecessarily treated white-coat hypertension from 
treated normalized hypertension with white-coat effect; the 
latter referring to patients with sustained hypertension whose 
out-of-office, but not in-office, BP normalized on antihyper-
tensive treatment.18
Limitations
These results should be interpreted by taking into account sev-
eral limitations. The major limitation of this kind of outcome 
studies is the lack of information during follow-up on BP lev-
els, treatment for hypertension, and other risk factors. Without 
repeated assessment during the years of follow-up, it is not 
known how many normotensive subjects developed hyper-
tension and how many untreated subjects received treatment, 
which probably influenced the outcome and may have diluted 
the true differences attributed to the white-coat and masked 
hypertension phenomena. Second, office BP was assessed at a 
single visit, which probably influenced the accuracy of hyper-
tension diagnosis and the prevalence of the white-coat and 
masked hypertension. Third, different home BP measurement 
numbers and schedules have been used in the studies included 
in the meta-analysis, which may have affected the findings. 
Finally, the treated group was significantly smaller than the 
untreated (22.5%) group, yet with much higher cardiovascu-
lar event risk that is largely attributed to higher frequency of 
established risk factors.
Perspectives
The present analysis suggests that the classification of individ-
uals on the basis of their office and home BP levels has signifi-
cant prognostic relevance, which seems to differ in untreated 
and treated subjects. Masked hypertension carries the same 
risk as sustained hypertension in both untreated and treated 
subjects, whereas white-coat hypertension is a risk factor in 
untreated but not in treated subjects.
These data should be taken into account in the management 
of hypertension in clinical practice. Home and ambulatory BP 
should not be considered as interchangeable methods for the 
detection of untreated white-coat hypertension. Because of 
the abovementioned limitations of the studies included in this 
meta-analysis, more data are required to confirm these find-
ings, by providing a direct comparison of home with ambula-
tory BP monitoring and with repeated assessment of BP levels 
and treatment status during follow-up.
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What Is New?
•	Most of the evidence on the prognostic relevance of white-coat and 
masked hypertension is based on ambulatory BP monitoring. This article 
based on a database including 6458 participants from 5 population stud-
ies provides evidence on the prognostic significance of these conditions 
detected by home BP measurements.
•	The database allowed separate powered analyses of the prognostic rel-
evance in untreated and treated subjects.
What Is Relevant?
•	The prognostic relevance of white-coat and masked hypertension de-
tected by home measurements differs in untreated and treated subjects.
•	Masked hypertension is associated with increased cardiovascular risk in 
both untreated and treated subjects.
•	 In contrast, white-coat hypertension is a cardiovascular risk factor in 
untreated but not in treated subjects. This finding is in the same direction 
with published data with ambulatory BP monitoring, although the latter 
did not reach significant difference compared with normotension.
Summary
Masked hypertension detected by home BP measurements is as-
sociated with increased cardiovascular risk in both untreated and 
treated subjects. However, white-coat hypertension is a cardiovas-
cular risk factor in untreated but not in treated subjects.
Home BP monitoring might not be interchangeable with ambula-
tory monitoring for the detection and prognosis of white-coat hy-
pertension in untreated subjects.
Novelty and Significance
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Table S1.  Hazard Ratios for Cardiovascular Events in Subjects with White-Coat, Masked and Sustained Hypertension versus 
Normotension Obtained after Excluding one Cohort at a Time 
 
Normotension White-Coat Hypertension Masked Hypertension Sustained Hypertension 
Excluded cohort 
Events/ 
Participants 
Events/ 
Participants 
Adjusted HR  
(95% CI) 
P 
Events/ 
Participants 
Adjusted HR  
(95% CI) 
P 
Events/ 
Participants 
Adjusted HR  
(95% CI) 
P 
Untreated subjects 
          
Ohasama 63/1650 28/394 1.43 (0.91-2.24) 0.12 23/235 1.43 (0.87-2.36) 0.16 90/718 2.01 (1.42-2.86) <0.0001 
Finn-Home 112/2190 48/454 1.64 (1.16-2.30) 0.0048 40/270 1.74 (1.20-2.52) 0.0038 83/489 2.41 (1.78-3.27) <0.0001 
Tsurugaya 150/2816 60/625 1.37 (1.01-1.85) 0.043 46/353 1.40 (1.00-1.97) 0.052 124/737 2.07 (1.60-2.68) <0.0001 
Didima 144/2587 58/642 1.31 (0.97-1.79) 0.082 50/373 1.54 (1.10-2.15) 0.011 130/844 2.10 (1.62-2.72) <0.0001 
Montevideo 147/2693 62/665 1.44 (1.07-1.94) 0.018 53/385 1.60 (1.16-2.22) 0.0044 137/908 2.10 (1.63-2.70) <0.0001 
Treated subjects 
          
Ohasama 25/166 18/132 1.25 (0.67-2.32) 0.48 26/135 1.28 (0.72-2.28) 0.40 80/508 1.21 (0.76-1.94) 0.42 
Finn-Home 50/254 37/150 1.22 (0.80-1.87) 0.36 56/171 1.80 (1.22-2.66) 0.0029 81/407 1.19 (0.83-1.71) 0.34 
Tsurugaya 48/269 43/200 1.27 (0.84-1.91) 0.26 54/176 1.84 (1.24-2.73) 0.0026 119/471 1.60 (1.13-2.27) 0.0079 
Didima 49/307 39/219 1.12 (0.73-1.71) 0.60 63/218 1.90 (1.30-2.79) 0.0009 122/613 1.51 (1.07-2.13) 0.019 
Montevideo 56/316 43/219 1.13 (0.76-1.68) 0.56 65/228 1.74 (1.21-2.51) 0.0028 134/645 1.43 (1.03-1.97) 0.031 
Hazard ratios express the risk versus the corresponding normotensive subgroup (untreated or treated respectively) and were stratified for cohort and adjusted for age, 
gender, body mass index, serum cholesterol, smoking status, cardiovascular disease history and diabetes mellitus. CI, confidence intervals. 
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Table S2.  Cardiovascular Risk Associated with Untreated and Treated White Coat, Masked and Sustained Hypertension Identified by 
Ambulatory or Home Blood Pressure Measurement Compared to Normotension (Adjusted Hazard Ratios+ with 95% Confidence Intervals 
in Parentheses) 
Database (method for  
BP measurements) 
Treatment n 
Follow-up 
(years) 
White coat 
hypertension 
Masked 
hypertension 
Sustained 
hypertension 
IDACO  
(daytime ambulatory)17 
No 5510 
9.5 
1.25 (0.86–1.82) 1.58* (1.17–2.12) 1.91* (1.48–2.45) 
Yes 1520 1.15 (0.76–1.75) 1.69* (1.12–2.57) 1.65* (1.19–2.30) 
IDACO  
(daytime ambulatory)18 
No 6439 
10.6 
1.17 (0.87–1.57) 1.67* (1.33–2.09) 1.43* (1.14–1.79) 
Yes 856 1.09 (0.79–1.52) 2.02* (1.40–2.90) 1.98* (1.55–2.53) 
IDHOCO present study 
(home) 
No 5007 
8.3 
1.42* (1.06–1.91) 1.55* (1.12–2.14) 2.13* (1.66–2.73) 
Yes 1451 1.16 (0.79–1.72) 1.76* (1.23–2.53) 1.40* (1.02–1.93) 
IDACO, International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome; IDHOCO, International Database of HOme blood pressure in 
relation to Cardiovascular Outcome; *, Statistically significant increase in risk; 
+
, Adjusted for cohort, sex, age, body mass index, serum cholesterol, smoking and 
drinking, diabetes mellitus, history of cardiovascular disease, and antihypertensive drug treatment.   
